Your Cart is Empty
Topical PDRN has promising early human evidence for certain tested preparations. That is different from proof that every PDRN serum works, or works like an injection. The useful question is what material reached which setting, what complete formula was applied and what a human study actually measured.
| Evidence type | What it can help establish | What it cannot establish alone |
|---|---|---|
| Cultured cells | Biological activity under direct exposure | Delivery through intact skin or visible consumer results. |
| Animal or excised skin | Experimental repair or transport behavior | Long-term effects in ordinary human skincare use. |
| Medical injections | Results for a defined treatment and condition | Efficacy of a cosmetic rubbed onto intact skin. |
| Human topical testing | Changes with the tested product and regimen | A result for all PDRN sources, concentrations or vehicles. |
Ye and colleagues’ 2026 study enrolled 31 women with self-reported sensitive skin. It compared a defined 0.1% PDRN eye cream with a 0.1% retinol cream in the same base, on opposite periocular sides, for 28 days. The authors reported greater changes on several cosmetic measurements with the PDRN preparation. There was no vehicle-only clinical arm, and the short duration leaves durability unresolved. These are findings for two specific preparations, not an ingredient-wide winner.
A small 2025 peony-derived PDRN study tested an experimental cream against a preparation without that material, including water-loss measurements after an irritant challenge. Another study evaluated plasma-modified PDRN in a short, 21-person cosmetic assessment. The latter’s clinical methods describe before-and-after measurements rather than a vehicle-controlled comparison. Modified materials and small studies should not be treated as interchangeable proof for a conventional serum.
Delivery depends on the material and vehicle. The 2026 work combined reconstructed-skin, porcine-skin and exploratory human Raman measurements. Its human delivery assessment involved one volunteer. Raman signals require cautious interpretation because skin already contains nucleic acids; the authors did not establish intracellular localization at single-cell resolution. “Penetrates” therefore needs a method, depth and formulation attached to it, not a universal yes or no.
A 2014 trial enrolled 216 people with chronic diabetic foot ulcers and used intramuscular and perilesional administration, as specified in the corrected record. That is a medical condition, route and endpoint. A healed ulcer is not a cosmetic fine-line or hydration measurement. Do not convert this evidence into a promise that an over-the-counter topical heals skin.
Ask whether its exact preparation was tested, whether a suitable control was used, and whether the endpoint matches the claim. A gene-expression change is not a wrinkle measurement. A laboratory scratch closing is not a wound healing on a person. Photos taken after a procedure cannot isolate the contribution of an accompanying serum.
Treat PDRN as an optional ingredient with developing evidence. For barrier goals or visible aging, keep established moisture care and sun protection. Follow finished-product directions on intact skin; post-procedure use requires the treating clinician’s instructions. Evidence does not set a guaranteed result deadline or a universal daily schedule.
Reviewed October 5, 2026. Educational skincare guidance; medical and procedural care requires an appropriate clinician.
